

WHAT IS CLAIMED IS:

1. A hybrid antigen comprising at least one antigenic domain of an infectious agent or tumor antigen and a binding domain that non-covalently binds to a heat shock protein, and wherein the binding domain comprises Asn Leu Leu Arg Leu Thr Gly Trp (SEQ ID NO:350), Phe Tyr Gln Leu Ala Leu Tyr Trp (SEQ ID NO:351), or Arg Lys Leu Phe Phe Asn Leu Arg Trp (SEQ ID NO:352).
5
2. The hybrid antigen of Claim 1 wherein a peptide linker separates the antigenic domain and the binding domain.
3. The hybrid antigen of Claim 1 wherein at least one of the antigenic domains is a T helper epitope.
10
4. A composition for inducing an immune response to an infectious agent or tumor antigen comprising at least one hybrid antigen of Claim 1.
5. A method for inducing an immune response to an infectious agent or tumor antigen comprising administering to a subject at least one hybrid antigen of Claim 1.
15
6. A method for inducing an immune response to an infectious agent or tumor antigen comprising administering to a subject a complex of:
 - (a) a hybrid antigen of Claim 1; and
 - (b) a heat shock protein;wherein the hybrid antigen and the heat shock protein are non-covalently bound.
20
7. The method of claim 6 wherein the heat shock protein is a hsp70.
8. A method for treating an infectious disease or cancer comprising administering to a subject at least one hybrid antigen of Claim 1, wherein at least one antigenic domain is from the infectious disease or cancer.
25

9. A method for treating an infectious disease or cancer comprising administering to a subject a complex of:
- (a) a hybrid antigen of Claim 1, wherein at least one antigenic domain is from the infectious disease or cancer; and
 - (b) a heat shock protein;
- wherein the hybrid antigen and the heat shock protein are non-covalently bound.
10. The method of claim 9 wherein the heat shock protein is a hsp70.
11. A hybrid antigen consisting essentially of at least one antigenic domain of an infectious agent or tumor antigen, a binding domain that non-covalently binds to a heat shock protein, and a peptide linker separating the antigenic domain and the binding domain, and wherein the binding domain comprises Asn Leu Leu Arg Leu Thr Gly Trp (SEQ ID NO:350), Phe Tyr Gln Leu Ala Leu Tyr Trp (SEQ ID NO:351), or Arg Lys Leu Phe Phe Asn Leu Arg Trp (SEQ ID NO:352).
12. The hybrid antigen of Claim 11 wherein at least one of the antigenic domains is a T helper epitope.
13. A composition for inducing an immune response to an infectious agent or tumor antigen comprising at least one hybrid antigen of Claim 11.
14. A method for inducing an immune response to an infectious agent or tumor antigen comprising administering to a subject at least one hybrid antigen of Claim 11.
15. A method for inducing an immune response to an infectious agent or tumor antigen comprising administering to a subject a complex of:
- (a) a hybrid antigen of Claim 11; and
 - (b) a heat shock protein;
- wherein the hybrid antigen and the heat shock protein are non-covalently bound.

16. The method of claim 15 wherein the heat shock protein is a hsp70.

17. A method for treating an infectious disease or cancer comprising administering to a
subject at least one hybrid antigen of Claim 11, wherein at least one antigenic domain is
5 from the infectious disease or cancer.

18. A method for treating an infectious disease or cancer comprising administering to a
subject a complex of:

- 10 (a) a hybrid antigen of Claim 1, wherein the antigenic domain is from the
infectious disease or cancer; and
(b) a heat shock protein;
wherein the hybrid antigen and the heat shock protein are non-covalently bound.

19. The method of claim 18 wherein the heat shock protein is a hsp70.

15

20. A peptide that is Asn Leu Leu Arg Leu Thr Gly Trp (SEQ ID NO:350), Phe Tyr Gln
Leu Ala Leu Tyr Trp (SEQ ID NO:351), or Arg Lys Leu Phe Phe Asn Leu Arg Trp (SEQ
ID NO:352).

20